Mesoblast (MESO) - 2024 Q2 - Quarterly Report

mesol February 2024 ASX: MSB; Nasdaq: MESO Global Leader in Allogeneic Cellular M« for Inflammatory Diseases Financial Results and Operational Update for the Half-Year Ended December 31, 2023 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Extensive patent portfolio with protection extending through 2040 Over 1,100 patents and patent applications (82 patent families) across all major jurisdictions Covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells Pro ...